Pacific Biosciences of California (NASDAQ:PACB) Upgraded at Wall Street Zen

Pacific Biosciences of California logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Pacific Biosciences from “sell” to “hold.” Analyst opinion remains cautious overall, with MarketBeat reporting a consensus “Reduce” rating and a $2.09 price target.
  • PacBio reported quarterly revenue of $40.56 million and a loss of $0.11 per share, beating analyst expectations for both metrics.
  • Financial risks remain: The company narrowed its 2026 revenue guidance to $155 million–$160 million, while falling gross margins and cash burn have raised concerns despite its 2028 cash-flow breakeven goal.
  • MarketBeat previews top five stocks to own in December.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings upgraded Pacific Biosciences of California from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, October 13th. Barclays lifted their price objective on Pacific Biosciences of California from $1.25 to $2.00 and gave the stock an "underweight" rating in a research report on Thursday. UBS Group assumed coverage on shares of Pacific Biosciences of California in a research note on Wednesday, September 9th. They issued a "neutral" rating and a $1.35 price target for the company. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $3.00 price target (up from $2.00) on shares of Pacific Biosciences of California in a research report on Thursday. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pacific Biosciences of California has an average rating of "Reduce" and a consensus price target of $2.09.

Read Our Latest Stock Report on PACB

Pacific Biosciences of California Trading Down 7.0%

PACB opened at $2.26 on Friday. The stock has a market capitalization of $702.48 million, a P/E ratio of -5.38 and a beta of 2.21. Pacific Biosciences of California has a 12 month low of $1.07 and a 12 month high of $3.43. The firm's fifty day simple moving average is $1.93 and its 200 day simple moving average is $1.62.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm had revenue of $40.56 million for the quarter, compared to analyst estimates of $39.31 million. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%. On average, equities research analysts predict that Pacific Biosciences of California will post -0.52 EPS for the current fiscal year.

Insider Activity at Pacific Biosciences of California

In other news, insider James Gibson, II sold 661,815 shares of the business's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total transaction of $2,058,244.65. Following the completion of the sale, the insider owned 1,083,848 shares in the company, valued at approximately $3,370,767.28. The trade was a 37.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the firm's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the transaction, the insider owned 2,705,853 shares in the company, valued at $3,057,613.89. The trade was a 0.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.70% of the company's stock.

Hedge Funds Weigh In On Pacific Biosciences of California

Hedge funds and other institutional investors have recently modified their holdings of the company. Essential Partners LLC purchased a new position in shares of Pacific Biosciences of California during the 1st quarter valued at about $25,000. Choreo LLC purchased a new position in shares of Pacific Biosciences of California during the third quarter valued at $27,000. Interchange Capital Partners LLC bought a new stake in shares of Pacific Biosciences of California in the 3rd quarter valued at approximately $28,000. Corient Private Wealth LP bought a new position in Pacific Biosciences of California during the 2nd quarter worth about $30,000. Finally, Pinegrove Venture Partners LLC bought a new position in Pacific Biosciences of California in the second quarter valued at approximately $34,584.

Pacific Biosciences of California News Summary

Here are the key news stories impacting Pacific Biosciences of California this week:

  • Positive Sentiment: PacBio reported third-quarter revenue of $40.56 million, above the $39.31 million consensus, and a loss of $0.11 per share, narrower than the expected $0.13 loss. Coverage also highlighted clinical adoption and AI partnerships as sources of growth. Zacks Q3 results Q3 deep dive
  • Positive Sentiment: Piper Sandler reaffirmed its Neutral rating but raised its price target to $3 from $2, indicating a more favorable valuation view. Piper Sandler rating
  • Neutral Sentiment: The company announced CFO changes; the report provided no further detail on the transition’s expected impact. CFO changes
  • Negative Sentiment: Management narrowed its 2026 revenue guidance to $155 million–$160 million. Analysts also pointed to falling gross margins and substantial cash burn, which raises concerns about the company’s financial position despite its target of cash-flow breakeven in 2028. Revenue guidance and breakeven target Q3 outlook analysis
  • Negative Sentiment: Barclays lifted its price target to $2 from $1.25 but maintained an Underweight rating, signaling continued caution about the shares. Barclays rating

About Pacific Biosciences of California

(Get Free Report)

Pacific Biosciences of California, Inc NASDAQ: PACB is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio's product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.

See Also

Analyst Recommendations for Pacific Biosciences of California (NASDAQ:PACB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pacific Biosciences of California Right Now?

Before you consider Pacific Biosciences of California, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacific Biosciences of California wasn't on the list.

While Pacific Biosciences of California currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines